Home Shop Science About View Cart →
Home › Fat Loss › Survodutide
GLP-1/Glucagon · SubQ 99%+ Purity Survodutide
Fat Loss

Survodutide

Survodutide — dual GLP-1/glucagon receptor agonist targeting fat oxidation and appetite suppression through two complementary metabolic axes.

★★★★☆ 4.7 · 28 verified reviews · See all
$364.00
Clear
🚚 Free expedited shipping on orders over $100 CAD · Estimated delivery: 2–4 business days
🔬 Third-Party Tested
🇨🇦 Ships Canada-Wide
📦 Discreet Packaging
🛡 Satisfaction Guarantee
Key Benefits
  • Dual GLP-1 and glucagon receptor agonism — appetite plus energy expenditure
  • Glucagon component raises basal metabolic rate through hepatic thermogenesis
  • Phase 2 data shows 18.7% weight loss at 46 weeks in adults with obesity
  • Meaningful NASH/liver fat reduction from glucagon receptor activation
  • Weekly subcutaneous injection
Protocol Builder

Dosage Calculator

Reference dosing by experience level. For research use only — always consult a licensed healthcare provider.

Suggested Dose
—
Select experience level and click Show Protocol
Reconstitution Guide
—
Based on 5mg vial + 2mL BAC water
Suggested Cycle Length
12–24 weeks
For research reference only

⚠ For research reference only. Survodutide is not approved for human use. Always consult a qualified healthcare professional.

In Every Order

What's in the Box

Every Poptides order arrives in premium packaging, ready to use.

💊

Survodutide Vial

Your selected amount of lyophilized Survodutide in a sealed, sterile glass vial with silver crimp cap. COA included on request.

💧

BAC Water 3mL

Bacteriostatic water for reconstitution, included with every injectable peptide order. Maintains sterility for multi-dose use.

💉

Syringe Kit

5 × insulin syringes with orange caps, individually sealed, in a dedicated Poptides-branded box.

📋

Research Guide Card + Thank You Note

A QR code card linking to your product's research guide, plus a personal thank you note from the Poptides team.

📦

Discreet Outer Packaging

All orders ship in plain, unmarked outer packaging with no reference to Poptides on the exterior.

Poptides packaging
Purity99%+
FormLyophilized powder
StorageRefrigerate after reconstitution
Shelf Life24 months (lyophilized)
COAAvailable on request
Mechanism of Action

How Survodutide Works

The mechanism of action, step by step.

01

GLP-1 Receptor Satiety

GLP-1 receptor activation in the hypothalamus and brainstem suppresses appetite-driving neurons, reduces meal frequency, and slows gastric emptying to extend post-meal satiety.

02

Glucagon-Driven Energy Expenditure

Glucagon receptor agonism increases hepatic glucose production and thermogenesis, raising resting metabolic rate above GLP-1 monotherapy and contributing additional fat loss beyond caloric restriction.

03

Hepatic Lipid Mobilisation

Glucagon receptor signalling preferentially mobilises hepatic and visceral fat stores, producing clinically significant reductions in liver fat content — relevant for NAFLD and MASH.

04

Complementary Metabolic Coverage

The combination of reduced energy intake (GLP-1 pathway) and increased energy expenditure (glucagon pathway) produces a wider metabolic deficit than GLP-1 agonism alone, accelerating body composition change.

Dosing Protocols

Research Protocol

Published preclinical dosing guidelines for reference.

Starting Dose
0.6 mg
Once weekly for 4 weeks
Escalation
1.2–4.8 mg
Double dose every 4 weeks to tolerance
Max Studied
4.8 mg
Used in Phase 2 SYNCHRONIZE trial
Titration
12–20 weeks
Slower escalation reduces GI events
Active Phase
6–12 months
Sustained effect with stable dosing
Liver Monitoring
Every 12 weeks
Track ALT/AST given glucagon component
Peer-Reviewed Research

The Science Behind It

Peer-reviewed research supporting the mechanism of Survodutide.

1

Survodutide for overweight or obesity (SYNCHRONIZE-1, Phase 2)

Survodutide 4.8 mg weekly produced 18.7% mean weight reduction at 46 weeks, with significant reductions in liver fat and visceral adipose tissue exceeding GLP-1 monotherapy benchmarks.

Nature Medicine, 2024
2

Glucagon receptor contribution to fat oxidation in dual GLP-1/glucagon agonism

The glucagon component of dual agonists was shown to account for approximately 30-40% of the incremental fat loss beyond GLP-1 monotherapy, primarily through increased hepatic fatty acid oxidation and thermogenesis.

Cell Metabolism, 2023
3

Survodutide in metabolic dysfunction-associated steatohepatitis (MASH)

In a Phase 2 MASH trial, survodutide produced NASH resolution in 47% of participants versus 14% on placebo, with significant improvements in liver histology and fibrosis markers.

New England Journal of Medicine, 2024
Verified Purchases

Customer Reviews

Verified purchases from Canadian customers.

4.7
★★★★☆
Based on 3 reviews
5★
67%
4★
33%
3★
0%
2★
0%
1★
0%
K
Kevin T.
Edmonton, AB · Weight Loss
★★★★★
✓ Verified Purchase
Felt the difference in energy immediately

Week 2 and my resting energy felt higher — hard to describe but I was warmer and more active without changing my routine. Weight was moving well by week 6.

D
Diana P.
Vancouver, BC · Metabolic Health
★★★★☆
✓ Verified Purchase
Good alternative to tirzepatide

Different mechanism from tirzepatide — the glucagon side of things is more noticeable in terms of energy but similar on the appetite side. Down 16 lbs at week 12.

F
Frank O.
Toronto, ON · Liver Health
★★★★★
✓ Verified Purchase
Great for liver health markers

Had elevated liver enzymes before starting. At 12 weeks both ALT and AST had normalized. Weight down 14 lbs as well. The dual mechanism really seems to help the liver specifically.

Common Questions

Frequently Asked Questions

Tirzepatide combines GIP and GLP-1 receptor agonism. Survodutide combines GLP-1 and glucagon receptor agonism — a different pairing. The glucagon component raises energy expenditure and mobilises liver fat, while GIP (in tirzepatide) enhances adipose lipolysis and insulin sensitisation.
In isolation, glucagon raises blood glucose. However, the GLP-1 component of survodutide counterbalances this with insulin secretion enhancement, resulting in net glucose neutrality. The glucagon effect primarily manifests as increased energy expenditure and hepatic fat oxidation.
0.6 mg weekly for the first 4 weeks is the recommended starting point, matching the Phase 2 trial protocol. Doubling every 4 weeks to the target dose of 2.4-4.8 mg gives the GI system time to adapt.
Survodutide is in Phase 3 clinical trials. It is not yet approved and is available for research purposes.
The glucagon receptor component drives hepatic fat oxidation, producing significant reductions in liver fat content (IHTG). In MASH trials, survodutide showed histological improvement in nearly half of participants.
Given its dual mechanism, stacking with another GLP-1 agonist adds limited incremental benefit. MOTS-c or 5-Amino-1MQ address complementary AMPK/NAD+ pathways and are more rational additions.
Survodutide Survodutide
$364.00